CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Clene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.29+0.19 (+6.13%)
Close on Oct 19, 2026
- Market cap
- $40.74M
- P/E (TTM)
- –
- Dividend yield
- –
Clene Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Drugs Segment [Member] | – | – | – | $0 | $0 | – | – | – | – |
| Supplements Segment [Member] | – | – | – | $473.00K | $723.00K | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | YoY |
|---|---|---|---|---|---|---|---|---|
| Drugs Segment [Member] | – | – | – | -$48.77M | -$50.18M | – | – | – |
| Supplements Segment [Member] | – | – | – | $360.00K | $205.00K | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $119.00K | $237.00K | $498.00K | $329.00K | $570.00K | $176.00K | – | 59.5% | -49.8% |
| Royalty [Member] | $81.00K | $105.00K | $156.00K | $144.00K | $153.00K | $30.00K | – | 40.5% | -22.9% |
By region
From the segment and revenue-disaggregation notes of Clene's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.